SCHEMBL21189286

SCHEMBL21189286

CCOC(=O)c1ccc(F)c2c1OCC[C@@H]2NCl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CREBBP Q92793 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TSHR P16473 3/20 0.36
HTR4 Q13639 2/20 0.36
TLR4 O00206 1/20 0.36
GAA P10253 2/20 0.36
TP53 P04637 1/20 0.36
HTT P42858 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 3/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21189287 0.83 MEN1 (0.37) NPSR1MAPK1SMN1; SMN2CREBBPHSD17B10
SCHEMBL21189246 0.79 TSHR (0.43) NPSR1HSD17B10TSHRGAATP53
SCHEMBL21189197 0.76 HTR2B (0.42) MAPK1SMN1; SMN2TP53HTTMEN1
SCHEMBL21189188 0.73 FADS1 (0.46) NPSR1SMN1; SMN2GAATP53HTT
SCHEMBL19991886 0.71 TSHR (0.41) NPSR1MAPK1HSD17B10TSHRTP53
SCHEMBL30474210 0.71 TSHR (0.46) NPSR1HSD17B10TSHRGAATP53
SCHEMBL21189238 0.68 TSHR (0.41) NPSR1HSD17B10TSHRGAATDP1
SCHEMBL12599573 0.68 TSHR (0.49) NPSR1MAPK1HSD17B10TSHRHTR4
SCHEMBL8310030 0.68 TSHR (0.40) NPSR1MAPK1HSD17B10TSHRGAA
SCHEMBL3694807 0.67 TSHR (0.53) NPSR1SMN1; SMN2HSD17B10TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS NPSR1 4645/4885MAPK1 2611/4885SMN1; SMN2 3837/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS NPSR1 4645/4885MAPK1 2611/4885SMN1; SMN2 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.